US extends expiration dates on J&J COVID vaccine to 6 months

Federal health regulators have again extended the expiration dates on Johnson & Johnson’s COVID-19 vaccine by another six weeks

Virus Outbreak California
Virus Outbreak California

Federal health regulators on Wednesday again extended the expiration dates on Johnson & Johnson's COVID-19 vaccine, providing health workers with six more weeks to use millions of doses of the shot.

The Food and Drug Administration said in a letter to J&J that the shots remain safe and effective for at least six months when properly stored and refrigerated. It's the second time the FDA has extended the shelf life on the vaccines since June, when the agency said they could be used for up to 4 1/2 months. When first authorized in February, the FDA said the vaccines could be stored for three months at normal refrigeration levels.

Health authorities in many states had recently warned that they could be forced to throw out thousands of doses of the one-shot vaccine without an extension.

The change gives health providers more time to use remaining shots sitting at pharmacies, hospitals and clinics. After plateauing earlier this summer, vaccination rates have begun climbing again as the contagious delta variant surges across many parts of the country.

Vaccine expiration dates are based on information from drugmakers on how long the shots stay at the right strength. J&J previously stated that it continues to conduct stability testing with the aim of further extending the shelf life of the shots.

The FDA has been reviewing expiration dates on all three U.S.-authorized vaccines as companies have continued to test batches in the months since the shots first rolled out. Vaccines from Pfizer and Moderna authorized in December, have a six-month shelf life.

J&J’s vaccine was highly anticipated because of its one-and-done formulation and easy-to-ship refrigeration.

But rival drugmakers Pfizer and Moderna, which started shipping shots months earlier, have already supplied more than enough doses to vaccinate all eligible Americans. More than 150 million Americans have been fully vaccinated with the companies’ two-dose shots. By comparison, just 13 million Americans have been vaccinated with the J&J shot.

Use of J&J’s vaccine has been hurt by several rare potential side effects. Earlier this month, U.S. health regulators added a new warning to the vaccine about links to a potentially dangerous neurological reaction called Guillain-Barré syndrome.

That followed a pause in the use of the shot in April after it was linked to a rare blood clot disorder. In both cases, government health advisers said the overall benefits of the shot still greatly outweigh the risks.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in